Episode 4 – Treatment paradigms in MS: right patient, right treatment, right time
01 września 2025
In Episode 4 of the Illuminoz podcast series, Bianca Stadler speaks with Professor Laura Airas – a neuroimmunologist from Finland – about how treatment strategies in multiple sclerosis have evolved.
Should clinicians begin with moderate-efficacy therapies and escalate, or start with high-efficacy treatments early on? What does the latest evidence suggest? And how do patient characteristics influence these decisions?
This episode explores the shift toward early, effective intervention, the importance of personalized care, and how biosimilars may help expand access to optimal treatment.
Informacje o podcaście:
“Illuminoz talks 2025” podcast series:
Episode 12 – PML: what is it, and why is it relevant in MS?
dr Tobias Bopp,
Episode 11 – Introducing biosimilar natalizumab
dr Heinz Wiendl,
Episode 10 – Patient conversations part three: the patient perspective
Ellen Tutton,
Episode 9 – Patient conversations part two: the nurse perspective
karolinamalicka,
Episode 8 – Patient conversations part one: the neurologist perspective
dr Agne Straukiene,
Episode 7 – Lessons learned part two: the value of biosimilars in rheumatology
prof. Paul Emery,
Episode 6 – Lessons learned part one: the value of biosimilars in oncology
prof. Kai Hübel,
Episode 5 – Biosimilars and MS: improving access to high-efficacy treatment
dr Barbara Kornek,
Episode 3 – MS treatment landscape part two: potential role of biosimilars
dr David Paling,
Episode 2 – MS treatment landscape part one: unmet needs
dr Luisa Klotz,
Episode 1 – Biosimilars: what are they, and why might they be important for MS?
dr Wallace Brownlee,
